NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Thursday, April 26th. Investors of record on Friday, May 11th will be paid a dividend of $0.34 per share on Friday, June 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.73%. The ex-dividend date is Thursday, May 10th. View Pfizer's Dividend History.

Pfizer declared that its board has approved a stock buyback plan on Tuesday, December 19th 2017, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company's management believes its shares are undervalued.

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.03. The biopharmaceutical company earned $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. Pfizer's revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.69 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

21 brokerages have issued 12 month price targets for Pfizer's stock. Their forecasts range from $36.00 to $45.00. On average, they anticipate Pfizer's share price to reach $40.4167 in the next year. View Analyst Ratings for Pfizer.

Pfizer saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 61,705,171 shares, an increase of 3.1% from the May 15th total of 63,688,761 shares. Based on an average trading volume of 19,319,820 shares, the short-interest ratio is presently 3.2 days. Currently, 1.1% of the company's stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

News stories about PFE stock have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a media sentiment score of 0.15 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.72%), Northern Trust Corp (1.31%), Massachusetts Financial Services Co. MA (1.04%), Dimensional Fund Advisors LP (0.79%), Franklin Resources Inc. (0.75%) and Barrow Hanley Mewhinney & Strauss LLC (0.69%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Swiss National Bank, FIL Ltd, Caisse DE Depot ET Placement DU Quebec, Levin Capital Strategies L.P., MUFG Securities EMEA plc and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., Neuberger Berman Group LLC, Mackay Shields LLC, Teacher Retirement System of Texas, LSV Asset Management and Summit Trail Advisors LLC. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $36.51.

Pfizer has a market capitalization of $217.34 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.